Fig. 4
From: Cost-effectiveness of dexamethasone compared with aflibercept in naïve diabetic macular edema
Cost-effectiveness scatterplot for aflibercept generated by MonteCarlo simulation. In quadrant I 46% of cases resulted, which means that the greater the cost, the greater the quality of life obtained. In quadrant II it is showed that in 11% of cases, the higher the cost, the fewer QALYs are obtained. In quadrant III 37% of cases resulted, which means that the fewer the cost, the fewer the quality of life obtained and 6% of cases resulted in quadrant IV, which means that the fewer the cost, the greater QALYs are obtained